MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1)

Frank Soldner, Michael Weller, Sibylle Haid, Stefan Beinroth, Scott W. Miller, Ullrich Wüllner, Robert E. Davis, Johannes Dichgans, Thomas Klockgether, Jörg B. Schulz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The molecular and biochemical mode of cell death of dopaminergic neurons in Parkinson's disease (PD) is uncertain. In an attempt at further clarification we studied the effects of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on dopaminergic PC12 cells. In humans and nonhuman primates MPTP/MPP+ causes a syndrome closely resembling PD. MPP+ toxicity is thought to be mediated by the block of complex I of the mitochondrial electron transport chain. Treatment of undifferentiated PC12 cells with MPP+ primarily inhibited proliferation of PC12 cells and secondarily led to cell death after the depletion of all energy substrates by glycolysis. This cell death showed no morphological characteristics of apoptosis and was not blocked by treatment with caspase inhibitors. The inhibition of cell growth was not dependent on an inhibition of complex I activity since MPP+ also inhibited cell proliferation in SH-SY5Y cells lacking mitochondrial DNA and complex I activity (p0 cells). As shown by flow cytometric analysis, MPP+ induced a block in the G0/G1 to S phase transition that correlated with increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) and growth arrest. Since treatment with I μM MPP+ caused apoptotic cell death in p21(WAF1/Cip1)-deficient (p21(-/-)) but not in parental (p21(+/+)) mouse embryo fibroblasts, our data suggest that in an early phase MPP+-induced p21(WAf1/Cip1) expression leads to growth arrest and prevents apoptosis until energy depletion finally leads to a nonapoptotic cell death.

Original languageEnglish (US)
Pages (from-to)75-85
Number of pages11
JournalExperimental Cell Research
Volume250
Issue number1
DOIs
StatePublished - Jul 10 1999
Externally publishedYes

Fingerprint

PC12 Cells
Cell Death
Parkinson Disease
Growth
1-Methyl-4-phenylpyridinium
Cyclin-Dependent Kinase Inhibitor p21
Apoptosis
Electron Transport Complex I
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Caspase Inhibitors
Dopaminergic Neurons
Phase Transition
Glycolysis
Mitochondrial DNA
S Phase
Primates
Therapeutics
Embryonic Structures
Fibroblasts
Cell Proliferation

Keywords

  • Cell cycle
  • Mitochondria
  • MPP
  • P21
  • Parkinson's disease
  • PC12

ASJC Scopus subject areas

  • Cell Biology

Cite this

MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). / Soldner, Frank; Weller, Michael; Haid, Sibylle; Beinroth, Stefan; Miller, Scott W.; Wüllner, Ullrich; Davis, Robert E.; Dichgans, Johannes; Klockgether, Thomas; Schulz, Jörg B.

In: Experimental Cell Research, Vol. 250, No. 1, 10.07.1999, p. 75-85.

Research output: Contribution to journalArticle

Soldner, F, Weller, M, Haid, S, Beinroth, S, Miller, SW, Wüllner, U, Davis, RE, Dichgans, J, Klockgether, T & Schulz, JB 1999, 'MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1)', Experimental Cell Research, vol. 250, no. 1, pp. 75-85. https://doi.org/10.1006/excr.1999.4504
Soldner, Frank ; Weller, Michael ; Haid, Sibylle ; Beinroth, Stefan ; Miller, Scott W. ; Wüllner, Ullrich ; Davis, Robert E. ; Dichgans, Johannes ; Klockgether, Thomas ; Schulz, Jörg B. / MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). In: Experimental Cell Research. 1999 ; Vol. 250, No. 1. pp. 75-85.
@article{5668fb98fe3f4898886bae192c8100d2,
title = "MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1)",
abstract = "The molecular and biochemical mode of cell death of dopaminergic neurons in Parkinson's disease (PD) is uncertain. In an attempt at further clarification we studied the effects of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on dopaminergic PC12 cells. In humans and nonhuman primates MPTP/MPP+ causes a syndrome closely resembling PD. MPP+ toxicity is thought to be mediated by the block of complex I of the mitochondrial electron transport chain. Treatment of undifferentiated PC12 cells with MPP+ primarily inhibited proliferation of PC12 cells and secondarily led to cell death after the depletion of all energy substrates by glycolysis. This cell death showed no morphological characteristics of apoptosis and was not blocked by treatment with caspase inhibitors. The inhibition of cell growth was not dependent on an inhibition of complex I activity since MPP+ also inhibited cell proliferation in SH-SY5Y cells lacking mitochondrial DNA and complex I activity (p0 cells). As shown by flow cytometric analysis, MPP+ induced a block in the G0/G1 to S phase transition that correlated with increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) and growth arrest. Since treatment with I μM MPP+ caused apoptotic cell death in p21(WAF1/Cip1)-deficient (p21(-/-)) but not in parental (p21(+/+)) mouse embryo fibroblasts, our data suggest that in an early phase MPP+-induced p21(WAf1/Cip1) expression leads to growth arrest and prevents apoptosis until energy depletion finally leads to a nonapoptotic cell death.",
keywords = "Cell cycle, Mitochondria, MPP, P21, Parkinson's disease, PC12",
author = "Frank Soldner and Michael Weller and Sibylle Haid and Stefan Beinroth and Miller, {Scott W.} and Ullrich W{\"u}llner and Davis, {Robert E.} and Johannes Dichgans and Thomas Klockgether and Schulz, {J{\"o}rg B.}",
year = "1999",
month = "7",
day = "10",
doi = "10.1006/excr.1999.4504",
language = "English (US)",
volume = "250",
pages = "75--85",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1)

AU - Soldner, Frank

AU - Weller, Michael

AU - Haid, Sibylle

AU - Beinroth, Stefan

AU - Miller, Scott W.

AU - Wüllner, Ullrich

AU - Davis, Robert E.

AU - Dichgans, Johannes

AU - Klockgether, Thomas

AU - Schulz, Jörg B.

PY - 1999/7/10

Y1 - 1999/7/10

N2 - The molecular and biochemical mode of cell death of dopaminergic neurons in Parkinson's disease (PD) is uncertain. In an attempt at further clarification we studied the effects of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on dopaminergic PC12 cells. In humans and nonhuman primates MPTP/MPP+ causes a syndrome closely resembling PD. MPP+ toxicity is thought to be mediated by the block of complex I of the mitochondrial electron transport chain. Treatment of undifferentiated PC12 cells with MPP+ primarily inhibited proliferation of PC12 cells and secondarily led to cell death after the depletion of all energy substrates by glycolysis. This cell death showed no morphological characteristics of apoptosis and was not blocked by treatment with caspase inhibitors. The inhibition of cell growth was not dependent on an inhibition of complex I activity since MPP+ also inhibited cell proliferation in SH-SY5Y cells lacking mitochondrial DNA and complex I activity (p0 cells). As shown by flow cytometric analysis, MPP+ induced a block in the G0/G1 to S phase transition that correlated with increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) and growth arrest. Since treatment with I μM MPP+ caused apoptotic cell death in p21(WAF1/Cip1)-deficient (p21(-/-)) but not in parental (p21(+/+)) mouse embryo fibroblasts, our data suggest that in an early phase MPP+-induced p21(WAf1/Cip1) expression leads to growth arrest and prevents apoptosis until energy depletion finally leads to a nonapoptotic cell death.

AB - The molecular and biochemical mode of cell death of dopaminergic neurons in Parkinson's disease (PD) is uncertain. In an attempt at further clarification we studied the effects of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on dopaminergic PC12 cells. In humans and nonhuman primates MPTP/MPP+ causes a syndrome closely resembling PD. MPP+ toxicity is thought to be mediated by the block of complex I of the mitochondrial electron transport chain. Treatment of undifferentiated PC12 cells with MPP+ primarily inhibited proliferation of PC12 cells and secondarily led to cell death after the depletion of all energy substrates by glycolysis. This cell death showed no morphological characteristics of apoptosis and was not blocked by treatment with caspase inhibitors. The inhibition of cell growth was not dependent on an inhibition of complex I activity since MPP+ also inhibited cell proliferation in SH-SY5Y cells lacking mitochondrial DNA and complex I activity (p0 cells). As shown by flow cytometric analysis, MPP+ induced a block in the G0/G1 to S phase transition that correlated with increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) and growth arrest. Since treatment with I μM MPP+ caused apoptotic cell death in p21(WAF1/Cip1)-deficient (p21(-/-)) but not in parental (p21(+/+)) mouse embryo fibroblasts, our data suggest that in an early phase MPP+-induced p21(WAf1/Cip1) expression leads to growth arrest and prevents apoptosis until energy depletion finally leads to a nonapoptotic cell death.

KW - Cell cycle

KW - Mitochondria

KW - MPP

KW - P21

KW - Parkinson's disease

KW - PC12

UR - http://www.scopus.com/inward/record.url?scp=0033542739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033542739&partnerID=8YFLogxK

U2 - 10.1006/excr.1999.4504

DO - 10.1006/excr.1999.4504

M3 - Article

C2 - 10388522

AN - SCOPUS:0033542739

VL - 250

SP - 75

EP - 85

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1

ER -